GLP-1s During Pregnancy Planning: What Prescribers Actually Require
GLP-1s are contraindicated in pregnancy. The 2-month washout period, what prescribers require for patients planning conception, the positive PCOS fertility data, and the oral contraceptive interaction.
GLP-1 medications and pregnancy planning require careful timing — the drugs are contraindicated in pregnancy, require washout before conception, and in some cases affect reproductive hormones. Here's what prescribers require and what the clinical guidance looks like.
The pregnancy contraindication
Semaglutide and tirzepatide are Category X equivalent — meaning animal studies show reproductive toxicity (fetal weight reduction and structural abnormalities in rodent studies) and the risk to a developing fetus isn't justified by the benefit in pregnancy. The drugs are contraindicated in pregnancy. This is in the prescribing label for Wegovy, Zepbound, and all GLP-1 obesity drugs.
Due to their long half-lives (semaglutide ~1 week, tirzepatide ~5 days), both drugs require washout before conception is attempted. Clinical recommendations: discontinue GLP-1 medications at least 2 months before attempting conception — some guidelines recommend longer given that a single dose may persist for several weeks and fetal development begins before most women know they're pregnant.
What prescribers require for patients planning pregnancy
Most telehealth GLP-1 prescribers will ask about pregnancy plans during intake. For women of childbearing age who indicate they're actively trying to conceive, responsible prescribers will typically: decline to prescribe or strongly advise against, provide the washout guidance, and document the discussion. Some will prescribe with explicit documentation that the patient understands the contraindication and plans adequate contraception.
GLP-1 and fertility: the positive data
The contraindication applies during pregnancy — not to fertility before conception. Emerging evidence (ENDO 2026 data, prior observational studies) suggests GLP-1 treatment may improve fertility in women with PCOS and obesity by reducing androgenic excess and improving insulin sensitivity. The clinical recommendation: treat with GLP-1 to improve metabolic health and PCOS, then discontinue 2 months before attempting conception.
Oral contraceptive timing with GLP-1
Women on GLP-1 and oral contraceptives: GLP-1s delay gastric emptying, which can reduce oral contraceptive peak absorption. Backup contraception for the first 2–4 weeks after GLP-1 initiation or dose increase is standard recommendation. This is a separate issue from the pregnancy contraindication — it's a drug interaction that may reduce contraceptive efficacy.
Verified telehealth providers
Women's health-experienced providers. Fertility and pregnancy planning discussion available.
Paid link Get started →